James Noble

James Noble

Chairman of the Board of Directors

Born 1959. Chairman of the Board of Directors since 2020.

M.A. from the University of Oxford.

Other appointments:

Board member of Adaptimmune since 2008. Board member and Deputy Chairman of GW Pharmaceuticals since 2007.

Previous appointments:

Brings more than 30 years of industry experience from both the private and the public sector, which includes: being co-founder of Adaptimmune and founder and CEO of Immunocore. Has also been Chairman and CEO of Avidex, which was aquired by Medigene. James has held several positions as board member at companies including, among others, Medigene, PowderJect Pharmaceuticals and CuraGen Corporation.

Does not hold any shares in Orexo.1

Holds bonds in Orexo amounting to a nominal value of SEK 2,500,000 (refers to the bond issue in February 2021).


Staffan Lindstrand

Staffan Lindstrand

Board member

Born 1962. Board member since 2002.

M.Sc. in Engineering.

Other appointments:

Partner of HealthCap since 1997, Board member of HealthCap AB, PulmonX Inc., Doctrin AB and The Swedish Association of Exchange-listed Companies.

Previous appointments:

Ten years in investment banking.

Holds 881 shares.1


Charlotte Hansson

Charlotte Hansson

Board member

Born 1969. Board member since 2020.

MSc. in Business Administration from Handelshögskolan at the University of Gothenburg.

Other appointments:

CFO at Systembolaget AB, since 2015.

Previous appointments:

Has been Group CFO & Executive VP at Cision AB. Charlotte has also been Group CFO at Addici AB. Before this she had an extensive career within business controlling, with many year at, for instance, Modern Times Group (MTG). 

Does not hold any shares in Orexo.1


Henrik Kjaer Hansen

Henrik Kjaer Hansen

Board member

Born 1976. Board member since 2018.

BSc. in Business Administration and a MSc. in Applied Economic and Finance at Copenhagen Business School.

Other appointments: 

Senior Director, Principal Investments, Novo Holdings A/S. Board member of Xellia Pharmaceutical.

Previous appointments:

Prior to joining Novo Holdings A/S, Kjaer Hansen was employed as a Senior Vice President in Moelis & Co. in London, focusing on healthcare M&A transactions. Other previous employments include Deutsche Bank and ABN AMRO, all in London.

Does not hold any shares in Orexo.1


David Colpman

David Colpman

Board member

Born 1961. Board member since 2015. B.Sc. Pharmacy.

Other appointments:

Director of Colpman Consulting Ltd since 2014. Member of the Royal Pharmaceutical Society. Board member of HRA Pharma and Forendo Pharma Ltd.

Previous appointments:

Former Head of Global Business Development 2012–2014, Senior Vice President of Business Development at Shire plc 1999–2012. Various business development and commercial positions at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals.

Holds 2,636 shares.1

 


 Kirsten Detrick

Kirsten Detrick

Board member

Boarn 1965. Board member since April 2016.

MBA.

Other appointments:

Managing Director at Takeda Austria GmbH and Takeda Osteuropa Holding GmbH since July, 2016.

Previous appointments:

Vice President Global Marketing, Therapeutic Area Commercial Lead – GI at Takeda Pharmaceuticals, Executive Director positions within US as well as Global Marketing and Commercialization at Amgen Inc. 2004–2013, Various marketing and commercial positions at Bristol-Myers Squibb 1991–2004. Former member of the Board of Southern California Biomedical Council and member of Healthcare Businesswomen’s Association.

Does not hold any shares in Orexo.1


Mary Pat Christie

Mary Pat Christie

Board member

Born 1963. Board member since 2019.

MBA.

Other appointments:

Board member of Hackensack Meridian Health’s Carrier Clinic and Restaurant Technologies. 

Previous appointments:

Managing Director at Angelo Gordon & Co., where she focused on business development of new fund strategies and new strategic alliances. Prior to that Mrs Christie worked at Cantor Fitzgerald as an Institutional Salesperson and was an original partner at the Seaport Group. Mary Pat was also the founder of Mendham Capital Management. Her career also includes high level roles at JP Morgan, Donaldson, Lufkin & Jenrette, and Fleet Bank.

Does not hold any shares in Orexo.1


Fred Wilkinson

Fred Wilkinson

Board member

Born 1956. Board member since 2019

MBA., B.Sc. Pharmacy

Other appointments:

Fred currently serves as board member of Alter Pharma Group.

Previous appointments:

Has served as President and Chief Executive Officer of Impax Laboratories, Inc. from 2014 until December 2016. Prior to that, Fred held the position of President of the Specialty business at Watson Pharmaceuticals, Inc. (currently Allergan) from 2009 through 2014. Other previous employments include among others President of Duramed Pharmaceuticals, Inc., Chief Executive Officer of Columbia Laboratories, and multiple positions at Sandoz Pharmaceutical Corp. Fred has previously served as board member of Impax Laboratories, Inc., Columbia Laboratories, Inc., Moksha8 Pharmaceuticals, Inc. and Somerset Pharmaceuticals, Inc.

Does not hold any shares in Orexo.1

As of December 31, 2020


Nikolaj Sørensen

Nikolaj Sørensen

President and CEO

Born 1972. President and CEO since 2013, employed since 2011.

B.Sc., and M.Sc., Copenhagen Business School, Denmark.

Other appointments:

Member of the Board, Bioservo Technologies AB.

Previous appointments:

Senior management positions at Pfizer Inc. with a focus on commercialization in Europe and Chairman of the Board and Managing Director at Pfizer AB. Prior to Pfizer Nikolaj Sørensen served as a management consultant at Boston Consulting Group (BCG), leading several projects within M&A, commercial transformation, and turn-arounds.

Holds 72,665 shares and stock options/share awards entitling to 354,483 shares.1


Robert A. DeLuca

Robert A. DeLuca

President Orexo US Inc.

Born 1961. President of Orexo US Inc. since 2013

R.Ph.

Other appointments:

Member of the St. John’s College of Pharmacy Dean’s Advisory Board, American Society of Addiction Medicine, Academy of Managed Care Pharmacy and the American and New Jersey Pharmacists Associations.

Previous appointments:

Extensive experience establishing commercial operations in the US with a combined background in market access, marketing, and sales. Has held leadership positions at multinational pharmaceutical companies including Sanofi-Aventis, Schering Plough, Berlex and Pharmacia, and most recently served as Chief Commercial Officer at Archimedes Pharmaceuticals.

Holds 8,568 shares and stock options/share awards entitling to 181,448 shares.1


Johannes Doll

Johannes Doll

EVP and Chief Commercial Officer

Born 1981. EVP and Chief Commercial Officer since 2019, employed since 2016.

MBA, University of Texas, and Dipl. Kaufmann, WHU Otto Beisheim School of Management, Germany.

Previous appointments:

EVP and Head of Corporate Development at Orexo, 2016-2018. Advisor to Orexo, 2013-2015.

Prior to Orexo, Johannes Doll worked at McKinsey & Company from 2004 to 2013, advising clients in the global pharmaceutical and private equity industry.

Holds 43,970 shares and stock options/share awards entitling to 78,216 shares.1


Dennis Urbaniak

Dennis Urbaniak

EVP Digital Therapeutics

Born 1969. EVP Digital Therapeutics since 2019.

Monmouth University, US, BS Business Administration/Marketing/English

Other appointments:

Member of HIMSS (Healthcare Information and Management Systems Society)

Previous appointments:

Chief Digital Officer, Havas Health & You, Chief Executive Officer, Havas Health Plus.  Prior to Havas, Managing Director Accenture Digital Life Sciences Analytics and Janssen Client Account Lead. Twenty years at Sanofi in various sales and marketing roles.

Previous volunteer experience as Board Member and Board Chair, Diabetes Hands Foundation; Executive Council Chairman, Center for Healthcare Innovation, and Executive Advisor to Monmouth University School of Science.

Holds 6,000 shares and stock options/share awards entitling to 33,400 shares.1


Michael Sumner

Michael Sumner

Chief Medical Officer

Born 1965. Chief Medical Officer since 2013.

MB BS, MRCP (UK), MBA.

Other appointments:

Scientific Advisory Board FirstString Research Inc.

Previous appointments:

Extensive experience within the pharmaceutical industry from Novartis Pharmaceuticals, Aventis Behring, Novo Nordisk and prior to joining Orexo held the position of Vice President Clinical and Medical Affairs at Shire.

Holds 21,805 shares and stock options/share awards entitling to 103,942 shares.1


Joseph DeFeo

Joseph DeFeo

EVP and Chief Financial Officer

EVP and Chief Financial Officer since 2018, employed since 2013.

Bachelor degree in accounting from Clarion University, US, and a MBA in finance from St. Joseph’s University, US.

Previous appointments:

Vice President, Finance & Administration at Orexo US Inc., 2013-2017. Priot to joining Orexo, Joseph DeFeo has worked in several senior finance positions among others establishing of US operations for a large Italian pharmaceutical company, Head of International Treasury and led finance for the commercial operations in the US for two major pharmaceutical companies. 

Holds 3,639 shares and stock options/share awards entitling to 82,054 shares.1


Cecilia Coupland

Cecilia Coupland

VP and Head of Operations

Born 1976. VP and Head of Operations since 2019, employed since 2006.

MSc in Chemical Engineering, Uppsala University, Sweden.

Previous appointments:

Head of Supply Chain & Planning at Orexo since 2014 and prior to that extensive experience of global pharmaceutical manufacturing and supply chain management, as well as drug development and project management, from various key positions at AstraZeneca and Orexo AB.

Holds 2,132 shares stock options/share awards entitling to 43,996 shares.1


Robert Rönn

Robert Rönn

VP and Head of R&D

Born 1976. VP and Head of R&D since 2019, employed since 2007.

MSc in Chemical Engineering and PhD in Medicinal Chemistry, Uppsala University, Sweden.

Previous appointments:

Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB.

Holds 1,741 shares and stock options/share awards entitling to 45,896 shares.1

As of December 31, 2020